Analysis suggests a deal between the UK and the US could lead to 229,000 excess deaths in England, a stark revelation as AstraZeneca's chief executive, Pascal Soriot, pushes for pharmaceutical companies to operate at "Chinese speed." This potential human cost underscores the deadly priorities embedded within Europe's economic and health policies, where corporate profit often eclipses public welfare, further eroding the social safety nets that are increasingly denied to migrants.
AstraZeneca, a British company headquartered in Cambridge, reported revenues of £30.7bn in the first half of 2026, marking a 6% increase from the previous year. The company aims for $80bn in annual sales by 2030, a significant jump from $59bn last year. These soaring profits highlight the vast wealth accumulated by pharmaceutical giants, while public health systems across Europe face chronic underfunding and austerity measures.
The Cost of Corporate Speed
Soriot, identified as the highest-paid FTSE 100 chief executive, insists the company's new drug pipeline remains "unmatched." His call for "Chinese speed" reflects a relentless pursuit of market dominance and profit maximization, a drive that often comes at the expense of equitable access to life-saving medicines. He acknowledged the surprise failure of Wainua, a major heart disease drug prospect, stating, "We have to accept to fail some of the time. Biology is biology." This acceptance of failure in drug development stands in stark contrast to the unforgiving policies of Fortress Europe, which doesn't offer such leniency to those seeking refuge and survival.
The CEO also dismissed concerns about job losses due to artificial intelligence, claiming it would increase productivity and make him "faster and smarter." He called the narrative of AI killing jobs "a bit of a fake story," a perspective that doesn't acknowledge the increasing precarity faced by workers across the continent. This drive for efficiency often translates into the exploitation of labor, particularly migrant workers who are routinely denied fair wages and secure employment, further dividing the working class along ethnic lines.
Soriot highlighted China's heavy investment in advanced pharmaceutical technologies, such as antibody drug conjugates and cell therapy. He urged Western companies to collaborate with China to bring drugs to global markets, framing competition in terms of market share rather than universal health access. This global market logic prioritizes capital movement and corporate expansion, while the movement of people seeking safety and opportunity is criminalised and met with fences and detention.
Priorities of Profit Over People
The controversial deal with the US, which could force the NHS to pay billions more for medicines, was struck under pressure from Donald Trump, who threatened heavy tariffs on UK drug exports. This agreement exemplifies how international trade deals can undermine national healthcare systems, turning essential medicines into commodities for profit. Such deals exacerbate the conditions of welfare chauvinism, where public services are systematically weakened, then used as a pretext to deny access to migrants, fueling racist narratives about "strained resources."
AstraZeneca plans to engage with the new UK government leader, Andy Burnham, to seek clarity on this deal. Soriot stated, "You have to establish your priorities and then fund them," a comment that rings hollow when public health is sacrificed for corporate gain. The true priorities of European governments aren't revealed in their rhetoric of human rights, but in their actions: the billions funneled into border militarization through agencies like Frontex, the expansion of detention centres, and the outsourcing of asylum screening, all while public services like healthcare are dismantled. This systemic defunding of public health disproportionately impacts the most vulnerable, including asylum seekers and undocumented migrants, who are often denied even basic medical care within the cruel machinery of the border regime.